Scarica l'app Stockscreener
6.72
2.44%
0.16
Dopo l'orario di chiusura:
6.59
-0.13
-1.93%
Precedente Chiudi:
$6.56
Aprire:
$6.61
Volume 24 ore:
183.04K
Relative Volume:
0.72
Capitalizzazione di mercato:
$141.32M
Reddito:
-
Utile/perdita netta:
$-52.07M
Rapporto P/E:
-32.35
EPS:
-0.2077
Flusso di cassa netto:
$-44.93M
1 W Prestazione:
-4.68%
1M Prestazione:
-9.80%
6M Prestazione:
-42.07%
1 anno Prestazione:
-49.76%
Intervallo 1D:
$6.50
$6.796
Intervallo di 1 settimana:
$6.25
$7.29
Portata 52W:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Nome
Cybin Inc
Settore
Industria
Telefono
908 764 8385
Indirizzo
100 King Street West, Suite 5600, Toronto
Confronta CYBN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.72 | 148.24M | 0 | -52.07M | -44.93M | -0.2077 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Borsa (CYBN) Ultime notizie
Cboe Canada Single Security - Cboe Global Markets
Cybin partners with Thermo Fisher for Phase 3 drug production By Investing.com - Investing.com Nigeria
Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus
AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset - Endpoints News
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus
Cybin (CYBN) Collaborates with Thermo Fisher for Phase 3 Development | CYBN Stock News - GuruFocus
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment - TipRanks
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin secures new patent for depression treatment drug - Investing.com
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - BioSpace
Cybin (CYBN) Secures U.S. Patent for CYB003 Program | CYBN Stock News - GuruFocus
Cybin secures new patent for depression treatment drug By Investing.com - Investing.com Nigeria
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder - marketscreener.com
Trading (CYBN) With Integrated Risk Controls - news.stocktradersdaily.com
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
Should You Buy, Sell, or Hold AppLovin Stock Before Q1 Earnings? - The Globe and Mail
Psychedelic drug developer Cybin partners with Osmind - MSN
Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus
Cybin to Participate at the 28th Annual Milken Institute Global Conference - Bluefield Daily Telegraph
ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI - The Globe and Mail
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Prog - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
(CYBN) Trading Report - news.stocktradersdaily.com
Cybin (CYBN) Partners with Osmind for Psychedelic Therapy Launch - GuruFocus
Psychedelic drug developer Cybin partners with Osmind (CYBN:NYSE) - Seeking Alpha
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - 01net
Cybin Partners With Osmind to Support Psychiatry Program Pipeline - marketscreener.com
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs | CYBN Stock News - GuruFocus
Cybin's Game-Changing Mental Health Partnership: 800+ Clinics to Deploy Novel Depression and Anxiety Treatments - Stock Titan
Where are the Opportunities in (CYBN) - news.stocktradersdaily.com
Cybin Inc Azioni (CYBN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Capitalizzazione:
|
Volume (24 ore):